ERBB2 and breast cancer: It should be noted that many new molecular targets, including phenotypic and genomic analysis, are prognostic and might have therapeutic effects on TNBC (Johnstone et al., 2020; Shan et al., 2019) Irrespective of the new molecular and genomic markers that have significant effect on the prognosis of BC, a more practical strategy for determining the basal-like TNBC and its prognosis is the use of HER2 by IHC to identify the protein expression surrogates for the basal-like gene signature (Toft and Cryns, 2011)